Could MGB Biopharma be on track to be the first developer of a truly novel antibacterial?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Could MGB Biopharma be on track to be the first developer of a truly novel antibacterial?
Released on: July 04, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    With the constant rise of drug resistant strains of bacteria, the race is on to develop novel treatments.
  • Summary
  • Transcript
  • Participants
  • Company
With the constant rise of drug resistant strains of bacteria, the race is on to develop novel treatments. MGB Biopharma's CFO, Raymond Spencer discusses with Adrian Dawkes the how the company will further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.
With the constant rise of drug resistant strains of bacteria, the race is on to develop novel treatments. MGB Biopharma's CFO, Raymond Spencer discusses with Adrian Dawkes the how the company will further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.
Raymond Spencer has over 25 years experience as a senior financial officer in biotech. For 12 years he was the CFO of LSE listed Antisoma plc. Whilst at Antisoma he was instrumental in completing the IPO in 1998, and in several fund-raising rounds, totalling over £100 million, as well as the acquisition of two private biotech companies. He was also instrumental in the closing of three licensing deals with big pharma.
MGB Biopharma
MGB Biopharma’s focus is to further develop their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds. The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000. There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective. The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, has recently completed a Phase I clinical safety study. MGB-BP-3 is just the first in our new exciting class of anti-infectives. MGB Biopharma commenced operations in 2010, and is funded by a syndicate of some of Scotland’s leading business angels, in co-operation with Scottish Enterprise.